Analysis of RNA MA Methylation Regulators and Tumour Immune Cell Infiltration Characterization in Prostate Cancer
Overview
Biotechnology
Authors
Affiliations
Potential roles of RNA N6-methyladenosine (mA) modification in tumour microenvironment (TME) cell infiltration has been demonstrated in recent studies. Nonetheless, the mechanism of its regulation remains unknown and immunotherapy has been marginal in prostate cancer. We demonstrated the expression of different mA regulators within prostate cancer related to genetic variation, alternative splicing (AS), tumour mutational burden (TMB) and TME. Unsupervised clustering and risk prediction model constructed by 24 mA regulators could predict scores of TME and prostate cancer patients prognosis. T cells CD8 was the intersection of immune cells which are related to multiple biological processes, and the fraction of T cells CD8 strongly correlates with immune associated gene sets. mA methylation modification and immune cells infiltration played a nonnegligible role in prostate cancer. Our study represents a step towards personalized immunotherapy for prostate cancer patients.
The Role of m6A Methylation in Tumor Immunity and Immune-Associated Disorder.
Mu S, Zhao K, Zhong S, Wang Y Biomolecules. 2024; 14(8).
PMID: 39199429 PMC: 11353047. DOI: 10.3390/biom14081042.
The role of RNA methylation in tumor immunity and its potential in immunotherapy.
Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L Mol Cancer. 2024; 23(1):130.
PMID: 38902779 PMC: 11188252. DOI: 10.1186/s12943-024-02041-8.
Role of N‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).
Pan J, Tong F, Ren N, Ren L, Yang Y, Gao F Oncol Rep. 2024; 51(6).
PMID: 38757383 PMC: 11110010. DOI: 10.3892/or.2024.8747.
Liyanage C, Fernando A, Chamberlain A, Moradi A, Batra J Cancers (Basel). 2024; 16(7).
PMID: 38610981 PMC: 11011207. DOI: 10.3390/cancers16071303.
Knowledge mapping and current trends of m6A methylation in the field of cancer.
Zhu C, Yang J, Zhang C, Wang Y, Wang J Heliyon. 2024; 10(4):e26262.
PMID: 38434062 PMC: 10906179. DOI: 10.1016/j.heliyon.2024.e26262.